Pfizer: ovarian cancer drug fails to meet trial goal

(CercleFinance.com) - Pfizer and its German partner Merck KGaA said on Monday that their treatment for ovarian cancer has failed to reach a primary endpoint in a late-stage trial.


A Phase III trial evaluating avelumab alone or in combination with chemotherapy did not meet the primary endpoints of overall survival or progression-free survival, the drugmakers said.

The multi-center, randomized study included 566 women with ovarian cancer that is resistant or refractory to platinum chemotherapy.

Shares of Pfizer are currently up 0.8 percent.

Copyright (c) 2018 CercleFinance.com. All rights reserved.